The mouse model with the corresponding mutation is also viable, expresses Atm with minimal activity, and lives long enough to develop B cell lymphomas and sarcomas beyond the thymic lymphomas [124]. Here, ATM is linked to B-cell non-Hodgkin lymphoma.